- Trial phase
- Phase 2 (completed)
- Time to market
- At least 4-6 years away, if ever. The drug has completed Phase II but has not yet initiated a Phase III trial, which typically takes 2-4 years to complete, followed by FDA review. ABVC's financial constraints also pose a significant hurdle to funding late-stage development.
- Why 3/10
- No hard dated catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for ABV-1505 in the next ~12 months. The drug has completed Phase II but has not advanced to Phase III, and no regulatory submission is pending. The impact score reflects the absence of a near-term binary event.
ABV-1505 has completed Phase II testing for adult ADHD with positive signals, but no Phase III trial has been initiated and no regulatory filing is scheduled. The next meaningful catalyst would be a Phase III start announcement or a partnership expansion, neither of which is currently dated. ABVC's financial fragility (recent dilutive convertible note, going concern risk) means any clinical progress depends on securing additional funding.
Price Chart
Executive Summary
ABV-1505 is a plant-based (botanical) drug candidate being developed by ABVC BioPharma (NASDAQ: ABVC) for adult ADHD. Its active ingredient, PDC-1421, is an extract from the herb Polygala tenuifolia. The drug completed Phase II testing at UCSF, showing statistically significant improvement on ADHD rating scales versus placebo with a favorable safety profile. ABVC licensed ABV-1505 (along with ABV-1504 for depression) to Xinnovation Therapeutics for the Chinese market in August 2023. However, no Phase III trial has been initiated, no regulatory submission is pending, and no registered ClinicalTrials.gov record was found for this specific drug. ABVC is a micro-cap company (~$0.91/share, ~$28M market cap) with zero product revenue, a going concern warning, and recent dilutive convertible note financing, making ABV-1505 a high-risk, early-stage asset with no near-term binary catalyst.
How It Works
ABV-1505 is a plant-based (botanical) drug candidate whose active ingredient, PDC-1421, is an extract from Polygala tenuifolia, a herb used in traditional Chinese medicine. It is being developed as a non-stimulant treatment for adult ADHD. The exact mechanism is not fully characterized but is thought to involve modulation of neurotransmitter systems in the brain, similar to how some antidepressants work, but derived from a natural plant source rather than being a synthetic chemical.
Trial Status
ABV-1505 completed Phase II Part I clinical trial at UCSF (results presented at the 2023 APSARD Conference). Phase II Part II was planned with sites in the US and Taiwan, but no completion announcement has been made. The company has stated the drug showed statistically significant improvement on ADHD rating scales vs placebo and was well tolerated with no serious adverse events. No Phase III trial has been initiated, and no ClinicalTrials.gov record was found for ABV-1505 specifically.
The Two-Sided Case
Upcoming Catalysts
- No hard dated catalysts are scheduled. Potential future catalysts include: announcement of Phase III trial initiation, update on Xinnovation Therapeutics licensing milestones, or additional partnership/licensing deals for the Chinese or other markets.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ABVC BIOPHARMA, INC. 424B4 ABVC ·Originating report